Breaking News
January 24, 2018 - Study illustrates role of specific antibodies in protection against influenza
January 24, 2018 - Curcumin could provide meaningful cognitive benefits, study suggests
January 24, 2018 - Tenax Therapeutics Announces Plan to Develop Levosimendan for a Pulmonary Hypertension Indication with No FDA Approved Therapies
January 24, 2018 - EndoBreak: Obesity in 2018; Diabetes Risks in Pregnancy
January 24, 2018 - Recommendations to improve the quality of ultrasound imaging in obstetrics and gynecology
January 24, 2018 - Sensory feedback facilitates enhanced brainwave control of portable hand-exoskeleton
January 24, 2018 - Innovative system helps medical staff to accurately evaluate patients’ risk of falling
January 24, 2018 - Porvair Sciences to showcase microplate and chromatography products at Analytica 2018
January 24, 2018 - Children with cochlear implant learn words faster than kids with normal hearing
January 24, 2018 - Ionis’ Inotersen NDA Accepted for Priority Review by the FDA
January 24, 2018 - Abuse-Deterrent Opioid No Help in Australia
January 24, 2018 - Maternal mortality rates are on the rise, but more accurate estimates are needed
January 24, 2018 - New essential oil inhaler facilitates pain management
January 24, 2018 - USPSTF: Insufficient Evidence to Screen Kids for Scoliosis
January 24, 2018 - Team develops method to identify seizure-causing regions in the brain
January 24, 2018 - New report takes comprehensive look at health effects of e-cigarettes
January 24, 2018 - Researchers develop new indicator for assessing active aging
January 24, 2018 - Research highlights decreasing trend in traditional hysterectomy
January 24, 2018 - Computer-based speech analysis has potential to improve prediction of psychosis
January 24, 2018 - New family of FFPE reagent kits launched by Beckman Coulter Life Sciences
January 24, 2018 - Researchers use epigenetic signatures to advance diagnosis for neurodevelopmental disorders
January 24, 2018 - EPI report reveals air quality as major environmental threat to public health
January 23, 2018 - How to Fight the Flu This Season
January 23, 2018 - Mixed Data for Fatty Acid Intake and Glaucoma
January 23, 2018 - The brains of jazz and classical pianists work differently
January 23, 2018 - Scientists identify protein biomarkers to track patients with Hutchinson-Gilford progeria syndrome
January 23, 2018 - Exercise could extend the life expectancy of breast cancer survivors, study states
January 23, 2018 - Researchers show association between microbiome and cancer-related blood infections
January 23, 2018 - Cancer.com Site Sat Dormant for 10 Years. Now It’s Live Again.
January 23, 2018 - FDA’s program to speed up drug approval shaved nearly a year off the process
January 23, 2018 - Study reveals key challenges and frustrations associated with current RTSM/IRT solutions
January 23, 2018 - Researchers unravel function of protein ‘smallish’
January 23, 2018 - Infants born in withdrawal due to opioid exposure in utero show abnormalities
January 23, 2018 - Researchers block common siren call of glioblastoma and metastatic breast cancer
January 23, 2018 - FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection
January 23, 2018 - Six Concerns About Practice Consolidation
January 23, 2018 - How Alzheimer’s Changes the Brain
January 23, 2018 - Pharmaceutical stirs outrage over price hike for brain tumor drug
January 23, 2018 - University under fire for off-the-grid herpes vaccine experiments
January 23, 2018 - Gastric environment permanently changes in the presence of Helicobacter pylori infection
January 23, 2018 - Scientists take tissue-engineering approach to improve healing related to skeletal system
January 23, 2018 - Consumption of dietary fiber can prevent obesity and metabolic syndrome, study shows
January 23, 2018 - FDA Alert: Multiple Drug Products by Flawless Beauty: Recall
January 23, 2018 - Rhymes with Amyloid: That’s Improbable!
January 23, 2018 - CLCN2-related leukoencephalopathy – Genetics Home Reference
January 23, 2018 - Can road salt and other pollutants disrupt our circadian rhythms?
January 23, 2018 - ‘Depression literacy’ program encourages many teens to seek adult help
January 23, 2018 - New initiative seeks to transform the way people live with dementia
January 23, 2018 - Isosec introduces first Virtual Smartcard for NHS Trusts and clinicians
January 23, 2018 - New report reveals rapid growth in Vietnam pharmaceutical market
January 23, 2018 - Obamacare Led to Rise in Breast Cancer Screening
January 23, 2018 - Bariatric Tx Bests Usual Care for Long-Term Health
January 23, 2018 - Keep Your Dogs and Cats Safe From Holiday Hazards
January 23, 2018 - New AI technology significantly improves human kidney analysis
January 23, 2018 - In Trump’s first year, anti-abortion forces make strides despite setbacks
January 23, 2018 - Small PFS Bump in Gastric/GEJ Cancer
January 23, 2018 - Defending against environmental stressors may shorten lifespan
January 23, 2018 - Researchers create cavitation bubbles to remove dental plaque
January 23, 2018 - Discovery offers fresh perspective on how the brain keeps its balance
January 23, 2018 - Opioid exposure linked to physical abnormalities in newborns
January 23, 2018 - Study identifies genes involved in latent asymptomatic state of breast cancer metastases
January 23, 2018 - Kala Pharmaceuticals Announces New Drug Application for Inveltys (KPI-121 1%) Has Been Accepted for Review by the U.S. Food and Drug Administration
January 23, 2018 - Closer Look at Household Contacts Finds More TB Cases
January 23, 2018 - Type 1 IFNs may mediate Zika pregnancy complications
January 23, 2018 - Anti-inflammatory pill could help make vaccines more effective for the elderly
January 23, 2018 - New discovery sheds light on iron-restricted anemia that causes fatigue in millions
January 23, 2018 - BMG LABTECH’s Australian office celebrates 20 years of innovation and growth in APAC region
January 23, 2018 - FDA Alert: Basic Drugs Brand of Senna Laxative by Magno-Humphries Laboratories: Recall
January 23, 2018 - Chronic Opioid Use High Among IBD Patients
January 23, 2018 - New long-acting, less-toxic HIV drug suppresses virus in humanized mice
January 23, 2018 - Findings provide better understanding of cognitive inflexibility in Fragile X Syndrome
January 23, 2018 - Powerful anti-oxidant can stop progression of fatty liver disease in young mice
January 23, 2018 - Marijuana use does not lower probability of conception, study shows
January 23, 2018 - Study shows value of occupational therapy in the lives of young adults with diabetes
January 23, 2018 - Chinese researchers develop multifunctional vehicle to transport gene therapeutics
January 23, 2018 - Researchers seek to understand effect of very low birth weight on the brain
January 23, 2018 - Be a Savvy Supermarket Shopper
January 23, 2018 - NIH Striving to Avoid False Hope in Chronic Fatigue
January 23, 2018 - ClinicalTrials.gov: Occupational Stress
January 23, 2018 - PrEP could make US easily hit its 2020 HIV prevention goal, study finds
Gene Therapy, New Drug Battle a Rare But Deadly Disease in Kids: MedlinePlus Health News

Gene Therapy, New Drug Battle a Rare But Deadly Disease in Kids: MedlinePlus Health News

image_pdfDownload PDFimage_print

HealthDay news image

WEDNESDAY, Nov. 1, 2017 (HealthDay News) — Babies born with a previously untreatable degenerative nerve disease now have two fresh sources of hope for their future.

Two innovative new therapies for spinal muscular atrophy (SMA) type 1 have proven highly effective in clinical trials, researchers report.

Babies with SMA are born without the gene that promotes production of survival motor neuron (SMN) protein. Without this protein, nerve cells in the spinal cord and brain stem stop working and start to die off.

These babies slowly lose the ability to move their arms and legs. Those with the most severe form, SMA type 1, eventually lose the ability to breathe on their own and rarely survive beyond 2 years of age.

Two research groups say they’ve produced breakthrough therapies for these children.

First, a new genetic treatment employed a DNA-loaded virus to replace the missing SMN1 gene with a fresh, healthy copy of the gene.

Second, an already-approved drug called nusinersen (Spinraza) was used to promote production of the crucial nerve protein by a backup gene called SMN2.

Both approaches increased survival in babies with SMA and preserved or improved their motor function, the researchers said.

“These are the first realistic treatment options for SMA,” said Dr. Ans van der Ploeg. She is chair of the Center for Lysosomal and Metabolic Diseases at Erasmus MC University in Rotterdam, the Netherlands.

Both therapies aim to increase production of SMN protein in the motor neurons and thereby improve the survival and function of motor neurons, she said. This leads to better muscle and respiratory function and survival, added van der Ploeg, who wrote an editorial accompanying the two clinical trial reports.

About one in every 11,000 babies is born with SMA, and six in 10 of them have type 1, said Dr. Richard Finkel. He is chief of neurology at Nemours Children’s Hospital in Orlando, Fla., and lead researcher of the nusinersen clinical trial.

The gene therapy treatment was tested in 15 babies with SMA type 1. All received one intravenous dose of a genetically engineered virus containing the new copy of the SMN gene. The virus is named AVXS-101. This was a phase 1 trial to test safety.

“We are trying to replace SMN1 with enough gene that works in enough nerve cells to change function,” said lead researcher Dr. Jerry Mendell, director of neuromuscular disorders and neurosciences at Nationwide Children’s Hospital in Columbus, Ohio.

All 15 patients treated with AVXS-101 are still alive, Mendell said, and some are thriving. Higher doses produced better responses.

“All the patients in the trial have improved with the exception of one,” Mendell said. “We have patients living out past three years now. And we had patients who actually could walk and run and play.”

Nusinersen was tested in 80 babies at 31 hospitals as part of a phase III trial prior to its 2016 approval.

“The drug is kind of novel,” Finkel said. “It’s not your standard off-the-shelf pharmacy kind of drug. It’s similar to a little piece of DNA.”

The drug targets the SMN2 gene, a backup gene to the SMN1 gene missing in these babies. It is injected into the spinal fluid. Patients undergo four “loading doses” via lumbar punctures within the first two months, and receive maintenance doses every four months, Finkel said.

Nusinersen amps up protein production by the SMN2 gene, potentially halting progression of nerve damage.

In the trial, 41 percent of infants who received the earliest treatment with nusinersen and 51 percent of infants in the final analysis experienced stable or improved motor function, the researchers reported.

Babies treated with nusinersen also were more likely to survive. The risk of death was 63 percent lower in the nusinersen group compared with the control group, the findings showed.

Results were so promising that the clinical trial was halted early so the control group could receive nusinersen, the study authors said.

“This study shows the drug has a clinically meaningful response with a higher likelihood of improved survival and motor function,” Finkel said.

Nusinersen, made by Biogen, is available for treatment now.

AVXS-101 will proceed to broader clinical trials involving more children at multiple hospitals, Mendell said.

Neither treatment had any clinically significant side effects, according to the researchers. The treatments do not constitute a full cure for children who have already developed symptoms of SMA. However, both research teams hope that kids treated before symptoms arise won’t suffer any degenerative nerve loss.

Finkel said, “If we can get these babies before they show these signs of weakness, I think that’s going to give the best chance for the most robust response, possibly even a cure.”

Van der Ploeg added that younger, less severely affected patients had a better chance of a good response in the trials. Also, while the gene therapy pilot trial results are promising, more data are required, she noted.

The nusinersen trial was paid for by Biogen and the drug’s developer, Ionis Pharmaceuticals. The AVXS-101 trial received funding from AveXis, developer of the designer virus.

Results of the studies were published in the Nov. 2 issue of the New England Journal of Medicine.

SOURCES: Ans van der Ploeg, M.D., Ph.D., chair, Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center, Rotterdam, the Netherlands; Richard Finkel, M.D., chief, neurology, Nemours Children’s Hospital, Orlando, Fla.; Jerry Mendell, M.D., director, neuromuscular disorders and neurosciences, Nationwide Children’s Hospital, Columbus, Ohio; Nov. 2, 2017, New England Journal of Medicine

News stories are written and provided by HealthDay and do not reflect federal policy, the views of MedlinePlus, the National Library of Medicine, the National Institutes of Health, or the U.S. Department of Health and Human Services.

Tagged with:

About author

Related Articles